Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
VKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.92 - $81.73
Previous CloseN/A
Volume7.75M
Average Volume (3M)7.37M
Market Cap
$2.91B
Enterprise Value$2.16B
Total Cash (Recent Filing)$33.88M
Total Debt (Recent Filing)$878.00K
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Oct 22, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding112,444,960
10 Day Avg. Volume13,764,261
30 Day Avg. Volume7,368,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-24.88K
Enterprise Value/Ebitda-10.18
Forecast
1Y Price Target
$90.59Price Target Upside247.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
EfficacyThe oral VK2735 demonstrated impressive weight loss of up to 12.2% compared to 1.3% for the placebo, showing competitive efficacy across multiple dose levels.
Long-term StrategyLonger term, oral '2735 is seen as a complement to VKTX's competitive subcutaneous '2735, with both efficacy and tolerability data appearing compelling.
Potential PartnershipThe potential for a large pharma partner to address manufacturing capacity issues at higher doses is promising.
Bears Say
Adverse EffectsSide effects came in higher than expectations as gastrointestinal adverse events like nausea, vomiting, diarrhea, and constipation featured prominently across all tested doses.
Discontinuation RatesDiscontinuation rates ranged from 20-38% in a largely dose-dependent manner, with the placebo arm having unusually high 18% discontinuations.
Market ReactionVKTX shares are under pressure following the data release and investor call, partly due to elevated expectations and concerns around the safety/tolerability profile of oral '2735.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $18.92 and its highest was $81.73 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $2.91B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Oct 22, 2025 which is in 55 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Jul 24, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.446 by -$0.134.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 112,444,960 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.446. Following the earnings report the stock price went up 2.746%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.59 (247.89% Upside)
$90.59 (247.89% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 417.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $984.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.25%
12-Months-Change
Fundamentals
Return on Equity
-19.99%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented both significant advancements in clinical trials and a strong financial position, but these were offset by increased expenses and net loss. The progress in clinical programs, particularly the VK2735 obesity program, is promising, but financial challenges remain.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$90.59
▲(247.89% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Immunovant
―
Ownership Overview
2.81% Insiders
23.80% Mutual Funds
4.07% Other Institutional Investors
56.67% Public Companies and Individual Investors